# Algernon Pharmaceuticals awards DMT manufacturing contract to Dalton Pharma Services

Algernon Pharmaceuticals awarded a contract to Dalton Pharma Services to manufacture the active pharmaceutical ingredient and finished product for its DMT formulation (AP-188) for a stroke program. Work has begun on the synthesis.

- Type: Contract
- Announced: 2021-02-19
- Where: Canada
- Status: announced
- Products: DMT active pharmaceutical ingredient, finished drug product
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Algernon Pharmaceuticals](https://endata.com/companies/53350.md) (customer)
- [Dalton Pharma Services](https://endata.com/companies/53351.md) (supplier)

## Sources

- [dalton.com](https://www.dalton.com/blog/2021/02/19/dalton-pharma-stroke-program), 2021-02-19: "We are very pleased to have appointed Dalton Pharma Services to synthesize our GMP DMT supply."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.